Table 2 Association between anti-p53 and anti-KRas antibodies and clinico-pathologic characteristics (p-values were calculated using the chi-squared test)
Characteristics | Anti-p53 antibody | Anti-KRas antibody | |||||
|---|---|---|---|---|---|---|---|
Negative | Positive | p-value | Negative | Positive | p-value | ||
Gender | Female | 6 (10) | 3 (12.5) | 0.7 | 9 (14) | 0 (0) | 0.09 |
Male | 54 (90) | 21 (87.5) | 56 (86) | 19 (100) | |||
Age (years) | < 60 | 25 (42) | 17 (71) | 0.02 | 32 (49) | 10 (53) | 0.8 |
≥ 60 | 35 (58) | 7 (29) | 33(51) | 9 (47) | |||
Histology | ACE | 25 (42) | 2 (8) | 0.003 | 24 (37) | 3 (16) | 0.08 |
SCCE | 35 (58) | 22 (91) | 41 (63) | 16 (84) | |||
Karnofsky Performance status | ≤ 80 | 23 (38) | 14 (61) | 0.06 | 27 (42) | 10 (53) | 0.4 |
90-100 | 37 (62) | 9 (39) | 37 (58) | 9 (47) | |||
Weight loss ≥ 10%% | No | 33 (57) | 9 (37.5) | 0.1 | 34 (53) | 8 (44) | 0.5 |
Yes | 25 (43) | 15 (62.5) | 30 (47) | 10 (56) | |||
Dysphagia | Solid | 49 (82) | 15 (62.5) | 0.06 | 48 (74) | 16 (84) | 0.4 |
Liquid | 11 (18) | 9 (32.5) | 17 (26) | 3 (16) | |||
Hemoglobin level < 120 g/L | Yes | 40 (37) | 17 (29) | 0.5 | 20 (31) | 9 (47) | 0.2 |
No | 20 (63) | 7 (71) | 45 (69) | 10 (53) | |||
T Stage | 1-2 | 12 (20) | 1 (4) | 0.07 | 12 (18) | 1 (5) | 0.2 |
3-4 | 48 (80) | 23 (96) | 53 (82) | 18 (95) | |||
N Stage | 0 | 19 (32) | 9 (37.5) | 0.6 | 22 (34) | 6 (32) | 0.9 |
1-2 | 41 (68) | 15 (62.5) | 42 (66) | 16 (68) | |||
M Stage | Non | 49 (82) | 18 (75) | 0.5 | 52 (80) | 15 (79) | 0.9 |
Oui | 11 (18) | 6 (25) | 13 (20) | 4 (21) | |||